Assessment of Weight Gain Post Treatment with Biological Compounds among A Sample of Patients Attending Baghdad Teaching Hospital

Atta Ahmous Al Sarray M.B-Ch.B.MSc.Ph.D*

*Assistant professor, College of health and medical technologies, Technical Middle University, e.mail: ata.alrubayi@yahoo.com

Abstract:

Objective: to evaluate the increase in weight after biological agents and the association of weight gain with the body mass index among a sample of patients attending Baghdad Teaching Hospital

Methods: A prospective study is carried out in Baghdad teaching hospital biological units and outpatient clinic of rheumatology for a period of one year starting On April 2015 and ending on March 2016. 120 patients were included in the study 40 psoriatic arthritis, 40 ankylosing spondylitis and 40 rheumatoid arthritis

Results: The study findings indicate that significance differences are seen regarding weight gain and biological agents (Infliximab, Etanercept and Adalimumab) after one year of follow up of patients with psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis respectively. Highest percentage of weight gain was reported with infliximab and psoriatic arthritis with a mean differences of BMI and weight (7.34 & 12.85) respectively while lowest percentage of weight gain was reporter with Etanercept and Rheumatoid arthritis with a mean differences of BMI ant weight (5.94 & 8.61) respectively

Recommendations: The study recommends further studies on the relation between weight gain and biological therapies and how and why this medication causes this weight change and what can be done to explore the real reason for these increments in weight of patients

Key words: Weight, Biological Compounds, ‘Baghdad Teaching Hospital’
Introduction:

ike other medications ‘Infliximab’ can cause some adverse effects, and weight gain appears to be one of them. Although clinical studies conducted on “infliximab” before it was approved by the “FDA” do not show weight gain as a possible side effect, Decrease in body weight can occur in patients with chronic diseases and has been appeared in chronic inflammatory diseases such as ‘Rheumatoid Arthritis’, where it may result in profound weight loss (1). These changes may be due to the effects of ‘cytokines’ such as “TNF-α' and “interleukins” and also the level of disease activity. Currently, large numbers of biological agents have been introduced for the treatment of various diseases one of them is anti-TNF therapy which is approved for the treatment of many patients with inflammatory arthritis who fail to gain satisfactory disease control with conventional disease-modifying anti-rheumatic drugs. In ‘randomized clinical trials’ all of these biological agents have been shown to be effective in reducing clinical signs of inflammation in ‘Rheumatoid arthritis’, “spondyloarthropathy”. Side effects of anti-TNF therapy include activation of infections and reactivation of latent ‘Tuberculosis’. Other adverse effects are weight gain which is rarely reported in small observational studies in ‘Rheumatoid arthritis’ and spondyloarthropathy (1-2). These effects may be of great concern to some patients, especially females, and despite the benefits of these drugs, the adverse effects may lead to discontinuation of anti-TNF therapy. On other hands, inflammatory cytokines such as tumor necrosis factor (TNF) are considered the main mediators of cachexia (1-2). TNF, formerly named cachectin, can induce muscle loss directly by both stimulating muscle protein breakdown (3) and reducing the sensitivity of skeletal muscle cells to anabolic stimuli (4). Some studies reveal that people taking ‘infliximab’ may experience an increase in weight. In one of the studies conducted on patients with Crohn’s disease who are on infliximab therapy, it showed that patients gained about 60 to 75 pounds of body weight. Furthermore, the study revealed that in patients taking ‘infliximab’ for ‘rheumatoid arthritis’, an increase in weight was also apparent but not that dramatic. In patients with rheumatoid arthritis, weight is an important prognostic factor. Preliminary evidence has indicated that treatment with ‘anti-tumor necrosis factor therapy’ can affect the weight of patients with ‘rheumatoid arthritis’, but the relationship between improved prognosis and weight changes remains to be clarified.

Objective: to determine the increase in weight (WT) after biological agents and the association of weight gain with the body mass index among a sample of patients attending ‘Baghdad teaching hospital’

Methodology:

A prospective study was carried out in Baghdad teaching hospital, biological units and outpatient clinic of rheumatology for a period of one year starting on April 1st 2015 and ending on March 30 2016. A total 120 patients were included in the study (40 ‘psoriatic arthritis’ 40 ‘ankylosing spondylitis’ and 40 ‘rheumatoid arthritis’) according to certain inclusion criteria consist of three groups of patients 1st group psoriatic arthritis on biological agent(‘Infliximab’) and second group rheumatoid arthritis on biological agent(‘Etanercept’ ) and third group ‘ankylosing spondylitis’ on biological
agent (‘Adalimumb’) each groups had two measurement of weight and body mass index (‘BMI’) calculated as weight in kilograms divided by height in meters squared. At base line and second reading after one year after treatment.

**Statistical analysis:**

Analysis of data is carried out using the available statistical package of SPSS-20 (Statistical Packages for Social Sciences-version 20). Data are presented in simple measures of mean, standard deviation, using independent student-t-test for difference between two means. Statistical significance is considered whenever the P value equal or is less than 0.05

**Ethical considerations:** Informed consent was obtained from all participants.

**Results:**

**Table (1): Distribution of the Study Sample According to Weight Gain and Infliximab**

<table>
<thead>
<tr>
<th>List</th>
<th>‘Infliximab’</th>
<th>95% Confidence Interval of the Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After one year</td>
</tr>
<tr>
<td></td>
<td>Mean ±SD</td>
<td>Mean ±SD</td>
</tr>
<tr>
<td>BMI</td>
<td>21.47±1.71</td>
<td>28.81±2.78</td>
</tr>
<tr>
<td>WT</td>
<td>74.18±8.09</td>
<td>87.03±10.14</td>
</tr>
</tbody>
</table>

BMI: body mass index ,WT : weight ,SD: standard deviation , P.V: probability value

Significance differences are seen regarding body mass index and weight gain after one year of follow up of patients with ‘psoriatic arthritis’ and ‘Infliximab’ therapy, with a mean difference (7.34&12.85) respectively.
### Table (2): Distribution of the Study Sample According to Weight Gain and ‘Etanercept’

<table>
<thead>
<tr>
<th>List</th>
<th>‘Etanercept’</th>
<th>95% Confidence Interval of the Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After one year</td>
</tr>
<tr>
<td>BMI</td>
<td>22.27±1.18</td>
<td>28.21±3.88</td>
</tr>
<tr>
<td>WT</td>
<td>80.73±6.15</td>
<td>89.33±9.73</td>
</tr>
</tbody>
</table>

BMI: body mass index, WT: weight, SD: standard deviation, P.V: probability value

The present study shows a significance difference are seen regarding body mass index and weight gain after Etanercept treatment of patient presented with “rheumatoid arthritis”

### Table (3): Distribution of the Study Sample According to Weight Gain and Adalimumab.

<table>
<thead>
<tr>
<th>List</th>
<th>‘Adalimumab’</th>
<th>95% Confidence Interval of the Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After one year</td>
</tr>
<tr>
<td>BMI</td>
<td>22.74±1.71</td>
<td>27.99±6.80</td>
</tr>
<tr>
<td>WT</td>
<td>70.31±2.18</td>
<td>81.87±9.29</td>
</tr>
</tbody>
</table>

BMI: body mass index, WT: weight, SD: standard deviation, P.V: probability value

This table depicts significance differences which are seen regarding body mass index and weight gain after one year of follow up of patients of Adalimumab therapy and ankylosing spondylitis, with a mean difference (7.34 & 12.85) respectively.
Discussion:

Weight gain has been reported as side effects of anti-TNF in several studies. In patients with ‘rheumatoid arthritis(RA)’, weight is an important prognostic factor. Preliminary evidence has indicated that treatment with anti-tumour necrosis factor (TNF) therapy can affect the weight of patients with “RA”, but the relationship between improved prognosis and weight changes remains to be clarified (5). The current study shows that a significance differences are seen regarding body mass index and weight after biological agent (Etanercept) of patient presented with rheumatoid arthritis this result is similar to other reported study (6). Weight gain has also been observed in a number of chronic inflammatory conditions other than RA, which have been treated with anti-TNF therapy. In a study of 106 patients with ankylosing spondylitis (AS), a significant weight increment was observed after year of treatment with anti-TNF therapy, (2) This was approved in the present study ,while highest percentage of weight gain is observed with psoriatic arthritis patients treated with Infliximab this result agree with other reported study (7). TNF –alpha is involved in body weight homeostasis and it is known to induce production and release of leptin , a satiety hormone there for it is possible that anti-TNF –alpha could led to decreased leptin level resulting in increased hunger and weight gain .this has been reported in multiple disease states treated with anti “TNF –alpha therapy”, including, ‘psoriasis’ , ‘spondyloarthropathy, ‘Crohn diseases’ (7,8) It is also suggested that ‘Infliximab’ can affect tumor necrosis factor (TNF) in the body. The interaction between “infliximab” and “TNF” may be the cause of weight gain in patients taking the drug either for “rheumatoid arthritis” or “Crohn’s disease”(9,10,11,12). Furthermore, some health care provider believes that the other active ingredients of “Infliximab” may be causing the weight gain. Currently, health experts are still inconclusive about the reason of weight gain more studies are required to determine how and why this medication causes this weight change and what can be done.

Recommendations: The study recommends further studies on the relation between weight gain and biological therapy and how and why this medication causes this weight change and what can be done to explore the real reason for these increments in weight of patients
References:


